CA3211381A1 - Novel darpin based multi-specific t-cell engagers - Google Patents
Novel darpin based multi-specific t-cell engagers Download PDFInfo
- Publication number
- CA3211381A1 CA3211381A1 CA3211381A CA3211381A CA3211381A1 CA 3211381 A1 CA3211381 A1 CA 3211381A1 CA 3211381 A CA3211381 A CA 3211381A CA 3211381 A CA3211381 A CA 3211381A CA 3211381 A1 CA3211381 A1 CA 3211381A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- recombinant protein
- binding
- amino acid
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Liquid Crystal Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158539P | 2021-03-09 | 2021-03-09 | |
| US63/158,539 | 2021-03-09 | ||
| US202163172973P | 2021-04-09 | 2021-04-09 | |
| US63/172,973 | 2021-04-09 | ||
| US202163265184P | 2021-12-09 | 2021-12-09 | |
| US63/265,184 | 2021-12-09 | ||
| PCT/IB2022/052126 WO2022190016A1 (en) | 2021-03-09 | 2022-03-09 | Novel darpin based multi-specific t-cell engagers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3211381A1 true CA3211381A1 (en) | 2022-09-15 |
Family
ID=81327872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3211381A Pending CA3211381A1 (en) | 2021-03-09 | 2022-03-09 | Novel darpin based multi-specific t-cell engagers |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11834504B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4304731A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024509904A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230155464A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022234894A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023018293A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3211381A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023012681A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305677A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010543A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022190016A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021403658A1 (en) * | 2020-12-16 | 2023-06-29 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| WO2022190016A1 (en) * | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| KR20230169182A (ko) * | 2021-04-09 | 2023-12-15 | 몰리큘라 파트너스 아게 | 신규한 DARPin 기반 CD70 인게이저 |
| JP2026524079A (ja) * | 2023-06-06 | 2026-07-17 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えcd2結合タンパク質及びその使用 |
| WO2025163082A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| KR20070085314A (ko) | 2004-11-12 | 2007-08-27 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 재조합 뉴캐슬 질환 바이러스 |
| KR101268939B1 (ko) | 2005-07-08 | 2013-05-30 | 유니버시티 오브 취리히 | 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이 |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2906591A1 (en) | 2012-10-15 | 2015-08-19 | Universität Zürich | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| US9458211B1 (en) | 2015-04-02 | 2016-10-04 | Molecular Partners Ag | Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains |
| US20180333296A1 (en) * | 2015-09-02 | 2018-11-22 | Dose Medical Corporation | Drug delivery implants as intraocular drug depots and methods of using same |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| MY196882A (en) | 2016-09-22 | 2023-05-08 | Molecular Partners Ag | Recombinant binding proteins and their use |
| KR20200142525A (ko) | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| TW202010757A (zh) * | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| EP3856245A4 (en) * | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
| KR20220016944A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 개선된 안정성을 갖는 설계된 안키린 반복 도메인 |
| CA3139164A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| EP3980452A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| JP2022535564A (ja) | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| CN114945584A (zh) | 2019-12-11 | 2022-08-26 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| AU2021271131A1 (en) | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| US20240108746A1 (en) | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| AU2021403658A1 (en) | 2020-12-16 | 2023-06-29 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| US20240317852A1 (en) | 2021-03-09 | 2024-09-26 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| WO2022190016A1 (en) * | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| KR20230169182A (ko) | 2021-04-09 | 2023-12-15 | 몰리큘라 파트너스 아게 | 신규한 DARPin 기반 CD70 인게이저 |
-
2022
- 2022-03-09 WO PCT/IB2022/052126 patent/WO2022190016A1/en not_active Ceased
- 2022-03-09 AU AU2022234894A patent/AU2022234894A1/en active Pending
- 2022-03-09 BR BR112023018293A patent/BR112023018293A2/pt unknown
- 2022-03-09 CA CA3211381A patent/CA3211381A1/en active Pending
- 2022-03-09 MX MX2023010543A patent/MX2023010543A/es unknown
- 2022-03-09 KR KR1020237031420A patent/KR20230155464A/ko active Pending
- 2022-03-09 US US17/654,209 patent/US11834504B2/en active Active
- 2022-03-09 IL IL305677A patent/IL305677A/en unknown
- 2022-03-09 EP EP22714542.2A patent/EP4304731A1/en active Pending
- 2022-03-09 JP JP2023554922A patent/JP2024509904A/ja active Pending
-
2023
- 2023-09-26 CO CONC2023/0012681A patent/CO2023012681A2/es unknown
- 2023-10-23 US US18/492,484 patent/US20240254229A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4304731A1 (en) | 2024-01-17 |
| US20230056271A1 (en) | 2023-02-23 |
| JP2024509904A (ja) | 2024-03-05 |
| IL305677A (en) | 2023-11-01 |
| MX2023010543A (es) | 2023-10-13 |
| US11834504B2 (en) | 2023-12-05 |
| CO2023012681A2 (es) | 2023-09-29 |
| US20240254229A1 (en) | 2024-08-01 |
| BR112023018293A2 (pt) | 2023-10-31 |
| AU2022234894A1 (en) | 2023-10-05 |
| KR20230155464A (ko) | 2023-11-10 |
| WO2022190016A1 (en) | 2022-09-15 |
| AU2022234894A9 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110041433B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| EP4245317A1 (en) | Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody | |
| US11834504B2 (en) | DARPin based multi-specific t-cell engagers | |
| CN114929751B (zh) | Ror1特异性嵌合抗原受体及其治疗应用 | |
| US20240052033A1 (en) | Recombinant cd3 binding proteins and their use | |
| JP7844012B2 (ja) | 抗IL13Rα2抗体、その抗原結合フラグメントおよび使用 | |
| US20220298212A1 (en) | Recombinant 4-1bb binding proteins and their use | |
| TW201936638A (zh) | 雙特異性異質二聚體雙功能抗體及彼等之用途 | |
| JP7138989B1 (ja) | メソテリンに特異的に結合する抗メソテリンキメラ抗原受容体 | |
| US20250074994A1 (en) | Novel darpin based cd70 engagers | |
| CN115335405B (zh) | 全人源抗人cd22的嵌合抗原受体及其应用 | |
| US11965033B2 (en) | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 | |
| WO2024099265A1 (zh) | 工程化嵌合抗原受体免疫细胞及其应用 | |
| EP4724486A1 (en) | Recombinant cd2 binding proteins and their use | |
| WO2025146490A1 (en) | Recombinant cd117 binding proteins and their use | |
| WO2026074086A1 (en) | Cells expressing chimeric antigen receptors and a glutamine transporter, uses and methods thereof | |
| WO2024248037A1 (ja) | Ccr8を抗原として認識する二重特異性抗体 | |
| CN120988140A (zh) | 双靶点嵌合抗原受体、免疫效应细胞及应用 | |
| CN117242100A (zh) | 基于DARPin的新型CD70接合物 | |
| CN117157327A (zh) | 基于darpin的新型多特异性t细胞接合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250225 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250225 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250225 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260223 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260304 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260316 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260316 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260316 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260316 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260316 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260317 |